RSV vaccine study for adults with chronic conditions
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You should be able to live independently and get around on your own.
- If you are 18 to 59, you need at least one stable chronic condition like heart disease, lung disease, diabetes, severe obesity, liver disease, kidney disease, a nerve disorder affecting breathing, or a blood disorder.
- You cannot have a bleeding disorder or a history of severe allergic reactions to vaccines.
- You must not have a weakened immune system or be taking certain immune-suppressing medications.
- You cannot have a history of Guillain-Barré syndrome or a serious unstable medical condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This trial tests a new RSV vaccine for people aged 60 and above. RSV is a common virus that can cause serious breathing problems in older adults. The study will see if the vaccine is safe and helps protect you from RSV.
This trial tests a new vaccine against respiratory syncytial virus (RSV), a common virus that can cause lung infections. It is for healthy adults aged 18 and older, to see if the vaccine is safe and produces a good immune response.
This trial studies whether giving a booster dose of the RSV vaccine (Abrysvo) is safe and effective for adults with weakened immune systems. It includes people who have never had an RSV vaccine and those who had one or two doses in the past.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
This study tests a new vaccine that may protect babies from a common breathing virus called RSV. It is given to healthy women to see if it is safe and if it helps the body make protection that could be passed to a baby during pregnancy.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.